Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Definition of a consensus binding site for p53

El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · see citing works

The Rb/E2F pathway: expanding roles and emerging paradigms

Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · see citing works

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

Friesen, C., Herr, I., Krammer, P. H., & Debatin, K. (1996) · Nature Medicine · doi:10.1038/nm0596-574 · Cited by 975 · see citing works

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works

p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878 · see citing works

Regulation ofp53downstream genes

El‐Deiry, W. S. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0097 · Cited by 797 · see citing works

Methods in Molecular Biology

Weedn, V. W. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.2.278 · Cited by 773 · see citing works

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 743 · see citing works

Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression

Owen‐Schaub, L. B., Zhang, W. K., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A., Zhang, W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 731 · see citing works

Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53

Chin, K., Ueda, K., Pastan, I. H., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726 · see citing works

Regulation and function of the p53 tumor suppressor protein

Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721 · see citing works

Role for the p53 homologue p73 in E2F-1-induced apoptosis

Irwin, M. S., Marín, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710 · see citing works

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint

Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652 · see citing works

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems

Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 624 · see citing works

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511 · see citing works

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464 · see citing works

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439 · see citing works

p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells

Como, C. J. D., Gaiddon, C., & Prives, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417 · see citing works

Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation

Weinmann, A. S., & Farnham, P. (2002) · Methods · doi:10.1016/s1046-2023(02)00006-3 · Cited by 349 · see citing works

The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation

Soussi, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332 · see citing works

Multiple roles of the tumor suppressor p53

Bargonetti, J., & Manfredi, J. J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00015 · Cited by 332 · see citing works

The p53 and Mdm2 families in cancer

Michael, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00264-7 · Cited by 288 · see citing works

Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes

Fusenig, N. E., & Boukamp, P. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199811)23:3 · Cited by 282 · see citing works

Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1

Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244 · see citing works

Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73

Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241 · see citing works

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control

Gualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 237 · see citing works

Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities

Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234 · see citing works

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

Cadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 225 · see citing works

Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities

Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M. G., Monti, O., Baccarini, A., Sal, G. D., Levrero, M., Sacchi, A., Oren, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201405200 · Cited by 225 · see citing works

High metastatic potential in mice inheriting a targeted p53 missense mutation

Liu, G., McDonnell, T. J., Luna, R. M. D. O., Kapoor, M., Mims, B. H., El‐Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 198 · see citing works

Activation of c- myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain

Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194 · see citing works

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160 · see citing works

Structural characteristics of CD40 ligand that determine biological function

Fanslow, W. C., Srinivasan, S., Paxton, R., Gibson, M. G., Spriggs, M. K., & Armitage, R. J. (1994) · Seminars in Immunology · doi:10.1006/smim.1994.1035 · Cited by 155 · see citing works

Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery

Offer, H., Wolkowicz, R., Matas, D., Blumenstein, S., Livneh, Z., & Rotter, V. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00505-0 · Cited by 144 · see citing works

Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling

Newton, K., & Strasser, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.195 · Cited by 144 · see citing works

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140 · see citing works

Human and Mouse Fas (APO-1/CD95) Death Receptor Genes Each Contain a p53-responsive Element That Is Activated by p53 Mutants Unable to Induce Apoptosis

Munsch, D., Watanabe-Fukunaga, R., Bourdon, J.-C., Nagata, S., May, E., Yonish-Rouach, E., & Reisdorf, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3867 · Cited by 131 · see citing works

The INK4a/ARF locus in murine tumorigenesis

Serrano, M. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.865 · Cited by 108 · see citing works

p53 Mutations: Gains or losses?

Michalovitz, D., Halevy, O., & Oren, M. (1991) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240450108 · Cited by 107 · see citing works

A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53‐null mammary epithelial cell mode .

Murphy, K. L., Dennis, A. P., & Rosen, J. M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0128com · Cited by 92 · see citing works

Fas Is Involved in the p53-Dependent Apoptotic Response to Ionizing Radiation in Mouse Testis1

Embree-Ku, M., Venturini, D. S., & Boekelheide, K. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.5.1456 · Cited by 92 · see citing works

Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells

Shao, R., Cao, C.-X., Nieves‐Neira, W., Dimanche‐Boitrel, M., Solary, É., & Pommier, Y. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204264 · Cited by 90 · see citing works

Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis

Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., & Rotter, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4163 · Cited by 87 · see citing works

Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants

Yang, X., Pater, A., & Tang, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202843 · Cited by 50 · see citing works

Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma

Volkmann, M., Schiff, J.-H., Hajjar, Y., Otto, G., Stilgenbauer, F., Fiehn, W., Galle, P. R., & Hofmann, W. J. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100244 · Cited by 45 · see citing works

A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity.

Lotem, J., & Sachs, L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9672 · Cited by 42 · see citing works

The Region 3′ to the Major Transcriptional Start Site of the MDR1 Downstream Promoter Mediates Activation by a Subset of Mutant P53 Proteins

Strauss, B. E., & Haas, M. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2781 · Cited by 33 · see citing works

Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer

Boldrini, L., Faviana, P., Pistolesi, F., Gisfredi, S., Quirico, D. D., Lucchi, M., Mussi, A., Angeletti, C. A., Baldinotti, F., Fogli, A., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204727 · Cited by 22 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

When mutants gain new powers: News from the mutant p53 field

Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · see citing works

Mutant p53 Gain-of-Function in CancerPreprint

Oren, M., & Rotter, V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

p53 and breast cancer, an update

Lacroix, M., Toillon, R., & Leclercq, G. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380 · see citing works

Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis

Dong, P., Karaayvaz, M., Jia, N., Kaneuchi, M., Hamada, J., Watari, H., Sudo, S., Ju, J., & Sakuragi, N. (2012) · Oncogene · doi:10.1038/onc.2012.334 · Cited by 307 · see citing works

p53 Family and Cellular Stress Responses in Cancer

Pflaum, J., Schlosser, S., & ller, M. M. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 294 · see citing works

p53 mutation heterogeneity in cancer

Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275 · see citing works

P53 and Prognosis

Vousden, K. H., & Prives, C. L. (2005) · Cell · doi:10.1016/j.cell.2004.12.027 · Cited by 259 · see citing works

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245 · see citing works

Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53

Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245 · see citing works

Transcription regulation by mutant p53

Weisz, L., Oren, M., & Rotter, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207 · see citing works

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202 · see citing works

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

Fontemaggi, G., Dell’Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., Terrenato, I., Mottolese, M., Muti, P. C., Domany, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1669 · Cited by 195 · see citing works

Regulation of AIF expression by p53

Stambolsky, P., Weisz, L., Shats, I., Klein, Y., Goldfinger, N., Oren, M., & Rotter, V (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401965 · Cited by 194 · see citing works

Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches

Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. Á., Ortíz-Sánchez, E., & García-Carrancá, A. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 189 · see citing works

Mutant p53 mediates survival of breast cancer cells

Lim, L. Y., Vidnovic, N., Ellisen, L. W., & Leong, C.-O. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605335 · Cited by 175 · see citing works

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163 · see citing works

Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis

Stein, Y., Rotter, V., & Aloni-Grinstein, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246197 · Cited by 161 · see citing works

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · see citing works

Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53Preprint

Pfister, N. T., & Prives, C. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026054 · Cited by 139 · see citing works

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)

Tan, B. S., Tiong, K. H., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.191 · Cited by 137 · see citing works

The role of Fas ligand and transforming growth factor β in tumor progression

Kim, R., Emi, M., Tanabe, K., Uchida, Y., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20270 · Cited by 137 · see citing works

p53-dependent Down-regulation of Telomerase Is Mediated by p21

Shats, I., Milyavsky, M., Tang, X., Stambolsky, P., Erez, N., Brosh, R., Kogan, I., Braunstein, I., Tzukerman, M., Ginsberg, D., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402502200 · Cited by 133 · see citing works

Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2

Wiech, M., Olszewski, M. B., Tracz‐Gaszewska, Z., Wawrzynów, B., Żylicz, M., & Żylicz, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051426 · Cited by 132 · see citing works

p53 downstream target genes and tumor suppression: a classical view in evolution

Rozan, L. M., & El‐Deiry, W. S. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402058 · Cited by 115 · see citing works

Regulators of Oncogenic Mutant TP53 Gain of Function

Yamamoto, S., & Iwakuma, T. (2018) · Cancers · doi:10.3390/cancers11010004 · Cited by 111 · see citing works

Mutant p53 Induces the GEF-H1 Oncogene, a Guanine Nucleotide Exchange Factor-H1 for RhoA, Resulting in Accelerated Cell Proliferation in Tumor Cells

Mizuarai, S., Yamanaka, K., & Kotani, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4629 · Cited by 111 · see citing works

Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer

Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 108 · see citing works

Differential regulation of the REGγ–proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells

Ali, A., Wang, Z., Fu, J., Ji, L., Liu, J., Li, L., Wang, H., Chen, J., Caulı́n, C., Myers, J. N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3667 · Cited by 104 · see citing works

The paradigm of mutant p53-expressing cancer stem cells and drug resistance

Shetzer, Y., Solomon, H., Koifman, G., Molchadsky, A., Horesh, S., & Rotter, V. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu073 · Cited by 102 · see citing works

Transcriptional activities of mutant p53: When mutations are more than a loss

Kim, E. L., & Deppert, W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20271 · Cited by 102 · see citing works

RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53

Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 99 · see citing works

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3

Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0336 · Cited by 96 · see citing works

p53 at the crossroads between cancer and neurodegeneration

Lanni, C., Racchi, M., Memo, M., Govoni, S., & Uberti, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.034 · Cited by 95 · see citing works

Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function

Gurtner, A., Starace, G., Norelli, G., Piaggio, G., Sacchi, A., & Bossi, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094813 · Cited by 92 · see citing works

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy

Bossi, G., Marampon, F., Maor-Aloni, R., ZANI, B. M., Rotter, V., Oren, M., Strano, S., Blandino, G., & Sacchi, A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6161 · Cited by 92 · see citing works

Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Osman, A. A., Neskey, D. M., Katsonis, P., Patel, A. A., Ward, A. M., Hsu, T., Hicks, S. C., McDonald, T. O., Ow, T. J., Alves, M. V. O., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2729 · Cited by 86 · see citing works

The Transcriptional Repressor hDaxx Potentiates p53-dependent Apoptosis

Gostissa, M., Morelli, M., Mantovani, F., Guida, E., Piazza, S., Collavin, L., Brancolini, C., Schneider, C., & Sal, G. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310801200 · Cited by 79 · see citing works

Mutant p53 proteins bind DNA in a DNA structure-selective mode

hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76 · see citing works

A New Family of Small Molecules To Probe the Reactivation of Mutant p53

Myers, M. C., Wang, Iera, J. A., Bang, J.-K., Hara, T., Saito, S., Zambetti, G. P., & Appella, D. H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja045752y · Cited by 76 · see citing works

Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs

Vikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75 · see citing works

Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression

Yan, W., Zhang, Y., Jin, Z., Liu, S., Cho, S. J., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.231639 · Cited by 70 · see citing works

Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II

Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., & Rotter, V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00374-07 · Cited by 70 · see citing works

p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells

Guo, X.-X., Li, Y., Sun, C., Jiang, D., Lin, Y., Feng-xie, J., Lee, S., & Jin, Y.-H. (2014) · Protein & Cell · doi:10.1007/s13238-014-0027-2 · Cited by 69 · see citing works

Increased Cell Surface Fas Expression Is Necessary and Sufficient To Sensitize Lung Fibroblasts to Fas Ligation-Induced Apoptosis: Implications for Fibroblast Accumulation in Idiopathic Pulmonary Fibrosis

Wynes, M. W., Edelman, B., Kostyk, A. G., Edwards, M. G., Coldren, C. D., Groshong, S. D., Cosgrove, G. P., Redente, E. F., Bamberg, A., Brown, K. K., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100447 · Cited by 68 · see citing works

Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses

Stravopodis (2009) · International Journal of Oncology · doi:10.3892/ijo_00000353 · Cited by 67 · see citing works

Induction of genetic instability by gain-of-function p53 cancer mutants

Xu, Y. (2008) · Oncogene · doi:10.1038/sj.onc.1211023 · Cited by 62 · see citing works

Identification of a putative p53 binding sequence within the human mitochondrial genome

Heyne, K., Mannebach, S., Wuertz, E., Knaup, K. X., Mahyar-Roemer, M., & Roemer, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.099 · Cited by 61 · see citing works

A balance between Raf-1 and Fas expression sets the pace of erythroid differentiation

Rubiolo, C., Piazzolla, D., Meissl, K., Beug, H., Huber, J. C., Kolbus, A., & Baccarini, M. (2006) · Blood · doi:10.1182/blood-2005-09-3866 · Cited by 59 · see citing works

Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers

Müller, M., Meyer, M., Schilling, T., Ulsperger, E., Lehnert, T., Zentgraf, H., Stremmel, W., Volkmann, M., & Galle, P. R. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.4.973 · Cited by 59 · see citing works

P53 transcriptional activities: A general overview and some thoughts

Millau, J., Bastien, N., & Drouin, R. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.06.002 · Cited by 58 · see citing works

Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase

Wang, X., Chen, J., Liu, Y., You, C., & Mao, Q. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1257-9 · Cited by 57 · see citing works

Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells

Yoshikawa, K., Hamada, J., Tada, M., Kameyama, T., Nakagawa, K., Suzuki, Y., Ikawa, M., Hassan, N. M. M., Kitagawa, Y., & Moriuchi, T. (2010) · Biomedical Research · doi:10.2220/biomedres.31.401 · Cited by 56 · see citing works

Mutant p53 and the Response to Chemotherapy and Radiation

Tchelebi, L. T., Ashamalla, H. L., & Graves, P. R. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_8 · Cited by 53 · see citing works

Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase

Yan, W., Jung, Y.-S., Zhang, Y., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103497 · Cited by 51 · see citing works

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53

Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50 · see citing works

Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell FormationPreprint

Shetzer, Y., Molchadsky, A., & Rotter, V. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026203 · Cited by 51 · see citing works

p53: a two-faced cancer gene

Kastan, M. B., & Berkovich, E. (2007) · Nature Cell Biology · doi:10.1038/ncb0507-489 · Cited by 49 · see citing works

p53 family members and chemoresistance in cancer: what we know and what we need to know

Gasco, M., & Crook, T. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.11.001 · Cited by 47 · see citing works

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression

Valenti, F., Ganci, F., Fontemaggi, G., Sacconi, A., Strano, S., Blandino, G., & Agostino, S. D. (2015) · Oncotarget · doi:10.18632/oncotarget.2587 · Cited by 44 · see citing works

ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters

Dell’Orso, S., Fontemaggi, G., Stambolsky, P., Goeman, F., Voellenkle, C., Levrero, M., Strano, S., Rotter, V., Oren, M., & Blandino, G. (2011) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2010.0084 · Cited by 42 · see citing works

Interactions of mutant p53 with DNA: guilt by association

Kim, E. L., & Deppert, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210312 · Cited by 42 · see citing works

Physical and Functional Antagonism between Tumor Suppressor Protein p53 and Fortilin, an Anti-apoptotic Protein

Chen, Y., Fujita, T., Zhang, D., Doan, H. Q., Pinkaew, D., Liu, Z., Wu, J., Koide, Y., Chiu, A., Lin, C. C.-J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217836 · Cited by 39 · see citing works

Characterization of Functional Domains Necessary for Mutant p53 Gain of Function

Yan, W., & Chen, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.097253 · Cited by 40 · see citing works

Cold atmospheric plasma as a potential tool for multiple myeloma treatment

Xu, D., Xu, Y., Cui, Q., Liu, D., Liu, Z., Wang, X., Yang, Y., Feng, M., Liang, R., Chen, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24649 · Cited by 38 · see citing works

Herpes simplex virus type 2 encodes a heat shock protein homologue with apoptosis regulatory functions

Michael, D. G. (2005) · Frontiers in bioscience · doi:10.2741/1736 · Cited by 38 · see citing works

Preferential Binding of Hot Spot Mutant p53 Proteins to Supercoiled DNA In Vitro and in Cells

Brázdová, M., Navrátilová, L., Tichý, V., Němcová, K., Lexa, M., Hrstka, R., Pečínka, P., Adámik, M., Vojtěšek, B., Paleček, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059567 · Cited by 37 · see citing works

p53: Its Mutations and Their Impact on Transcription

Vaughan, C. A., Pearsall, I., Yeudall, W. A., Deb, S. P., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_4 · Cited by 35 · see citing works

Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma

Schilling, T., Kairat, A., Melino, G., Krammer, P. H., Stremmel, W., Oren, M., & Müller, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.082 · Cited by 35 · see citing works

Eicosapentaenoic Acid Induces Fas-Mediated Apoptosis Through a p53-Dependent Pathway in Hepatoma Cells

Chi, T., Chen, G. G., & Lai, P. B. S. (2004) · The Cancer Journal · doi:10.1097/00130404-200405000-00009 · Cited by 35 · see citing works

Mutant p53 Protects Cells from 12- O -Tetradecanoylphorbol-13-Acetate–Induced Death by Attenuating Activating Transcription Factor 3 Induction

Buganim, Y., Kalo, E., Brosh, R., Besserglick, H., Nachmany, I., Rais, Y., Stambolsky, P., Tang, X., Milyavsky, M., Shats, I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0916 · Cited by 34 · see citing works

A Germ Line Mutation in the Death Domain of DAPK-1 Inactivates ERK-induced Apoptosis

Stevens, C., Lin, Y., Sanchez, M. R., Amin, E., Copson, E., White, H., Durston, V., Eccles, D., & Hupp, T. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m605649200 · Cited by 34 · see citing works

Deciphering the significance of p53 mutant proteins

Butera, A., & Amelio, I. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.06.003 · Cited by 33 · see citing works

Skp2B Overexpression Alters a Prohibitin-p53 Axis and the Transcription of PAPP-A, the Protease of Insulin-Like Growth Factor Binding Protein 4

Chander, H., Halpern, M., Resnick‐Silverman, L., Manfredi, J. J., & Germain, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022456 · Cited by 32 · see citing works

Mutant p53 (G199V) Gains Antiapoptotic Function through Signal Transducer and Activator of Transcription 3 in Anaplastic Thyroid Cancer Cells

Kim, T. H., Lee, S. Y., Rho, J. H., Jeong, N. Y., Soung, Y. H., Jo, W. S., Kang, D.-Y., Kim, S.-H., & Yoo, Y. H. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0117 · Cited by 30 · see citing works

Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter

Vaughan, C. A., Pearsall, I., Singh, S., Windle, B. E., Deb, S. P., Grossman, S. R., Yeudall, W. A., & Deb, S. (2016) · Oncotarget · doi:10.18632/oncotarget.6998 · Cited by 29 · see citing works

p53: Multiple Facets of a Rubik's Cube

Zhang, Y., & Lozano, G. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121926 · Cited by 26 · see citing works

Asparagine Dependency Is a Targetable Metabolic Vulnerability in TP53 -Altered Castration-Resistant Prostate Cancer

Yoo, Y. A., Quan, S., Yang, W., Guo, Q., Rodríguez, Y., Chalmers, Z. R., Dufficy, M. F., Lackie, B., Sagar, V., Unno, K., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2910 · Cited by 26 · see citing works

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability

Lü, Y., Cho, T., Mukherjee, S., Suarez, C. F., Foutel, N. S. G., Malik, A., Martinez, S., Dervovic, D., Oh, R. H., Langille, E. R., et al. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00032-x · Cited by 26 · see citing works

Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases

Pinkaew, D., & Fujise, K. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.06.006 · Cited by 23 · see citing works

Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer

Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 24 · see citing works

R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway

Lin, C., Liang, Y., Zhu, H., Zhang, J., & Zhong, X. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.09.022 · Cited by 22 · see citing works

Anti-Apoptotic NF-κB and “Gain of Function” mutp53 in Concert Act Pro-Apoptotic in Response to UVB+IL-1 via Enhanced TNF Production

Müller, I., Beissert, S., & Kulms, D. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.481 · Cited by 20 · see citing works

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22 · see citing works

S100A4 interacts with mutant p53 and affects gastric cancer MKN1 cell autophagy and differentiation

Shen, W., CHEN, D., Liu, S., Chen, L., Yu, A., FU, H., & Sun, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3209 · Cited by 19 · see citing works

Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.

Adhikari, A. S., & Iwakuma, T. (2009) · PubMed · doi:10.15017/15090 · Cited by 18 · see citing works

TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer

Nie, X., Liu, C., Guo, Q., Zheng, M., Gao, L., Li, X., Liu, D., Zhu, L., Liu, J., & Lin, B. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186080 · Cited by 18 · see citing works

Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner

Wamsley, J. J., Gary, C., Biktasova, A., Hajek, M., Bellinger, G., Virk, R. K., Issaeva, N., & Yarbrough, W. G. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.12 · Cited by 15 · see citing works

Regulators of Apoptosis in Cholangiocarcinoma

Jhala, N. C., Vickers, S. M., Argani, P., & McDonald, J. M. (2005) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2005-129-481-roaic · Cited by 14 · see citing works

Getting Back on Track,or what to do when apoptosis is de-railed: Recoupling Oncogenes to the Apoptotic Machinery

Fearnhead, H. O. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.1.538 · Cited by 10 · see citing works

p53: Balancing tumour suppression and implications for the clinic

Buganim, Y., & Rotter, V. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70037-1 · Cited by 9 · see citing works

Complementation of two mutant p53: Implications for loss of heterozygosity in cancer

Demidenko, Z. N., Fojo, T., & Blagosklonny, M. V. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.03.012 · Cited by 9 · see citing works

Immunohistochemical detection of P53 and MDM2 and its correlation with histological grading system in ovine pulmonary adenocarcinoma

Mustafa, E. S., Al-Jameel, W. H., & Al-Mahmood, S. S. (2021) · Al-mağallaẗ al-ʻirāqiyyaẗ li-l-ʻulūm al-bayṭariyyaẗ/Iraqi journal of veterinary sciences · doi:10.33899/ijvs.2021.127779.1527 · Cited by 8 · see citing works

Delayed caspase‐8 activation and enhanced integrin β1‐activated FAK underpins anoikis in oesophageal carcinoma cells harbouring mt p53‐R175H

Fanucchi, S., & Veale, R. B. (2011) · Cell Biology International · doi:10.1042/cbi20100894 · Cited by 8 · see citing works

TP53 Intronic Mutations in Bovine Enzootic Hematuria–Associated Urinary Bladder Tumors

Sasani, F., Baghban, F., Brujeni, G. N., & Kazemi, M. (2012) · Veterinary Pathology · doi:10.1177/0300985812469632 · Cited by 7 · see citing works

No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells

Fritzsche, C., Zeller, G. C., Knaup, K. X., & Roemer, K. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000136878.96680.f5 · Cited by 7 · see citing works

Advances on mutant p53 research

Li, D. (2008) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2008.00697 · Cited by 6 · see citing works

Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells.

Sheard, M. A., Uldrijan, S., & Vojtěšek, B. (2003) · PubMed · Cited by 43 · see citing works

p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878 · see citing works

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53

Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50 · see citing works

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · see citing works

Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma

Schilling, T., Kairat, A., Melino, G., Krammer, P. H., Stremmel, W., Oren, M., & Müller, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.082 · Cited by 35 · see citing works